Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results.
Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...
0.0 THE SEED Paper_0_0___THE_SEED__The_Codex_of_Recursive_Becoming_v1.1 0.1 THE FIELD Paper_0_1___THE_FIELD__The_Codex_of_Recursive_Ontology_v1_0 0.2 THE FIELDPRINT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results